Media stories about CryoPort (NASDAQ:CYRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CryoPort earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.273212528459 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of CryoPort (NASDAQ CYRX) opened at 7.75 on Friday. CryoPort has a 52-week low of $1.80 and a 52-week high of $8.23. The stock’s market capitalization is $191.22 million. The firm has a 50-day moving average price of $6.26 and a 200-day moving average price of $4.02.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $2.84 million. CryoPort had a negative return on equity of 67.75% and a negative net margin of 102.89%. On average, analysts predict that CryoPort will post ($0.72) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/08/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cryoport-nasdaqcyrx-share-price-updated.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
What are top analysts saying about CryoPort Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoPort Inc. and related companies.